Recombinant Rat IL-1β
| Code | Size | Price |
|---|
| LEI-I-212-10ug | 10 ug | £443.00 |
Quantity:
| LEI-I-212-50ug | 50 ug | £512.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rat
Regulatory Status: RUO
Shipping:
Ambient
Storage:
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
Further Information
Format:
This recombinant protein was lyophilized from a 0.2 um filtered solution in MES, EDTA, Dithiothreitol (DTT), sodium chloride (NaCl) and polyethylene glycol 8000 (PEG 8000).
Formulation:
This recombinant protein was lyophilized from a 0.2 um filtered solution in MES, EDTA, Dithiothreitol (DTT), sodium chloride (NaCl) and polyethylene glycol 8000 (PEG 8000).
Long Description:
IL-1R1 is an 80 kD transmembrane glycoprotein and a member of the Ig superfamily. IL-1 binds both IL-1R1 and IL-1R2. The ligands IL-1α and IL-1β only commence when binding IL-1R1 because IL-1R2 acts as a decoy receptor and competitively antagonizes the binding of IL-1α and IL-1β, thereby reducing their biological effects. Binding of the ligands to IL-1R1 is enhanced by an accessory protein, IL-1R-AcP. IL-1α can exist as either a 31 kD precursor or an 18 kD mature form. IL-1α is a proinflammatory cell-associated cytokine and IL-1β is a 17.5 kD proinflammatory secreted cytokine. Both IL-1α and IL-1β bind to the same receptor and have similar properties that include stimulation of thymocyte proliferation via IL-2 release, B-cell maturation and proliferation, mitogenic FGF-like activity and the ability to stimulate the release of prostaglandin and collagenase from synovial cells. Furthermore, IL-1β mediates a variety of immune and inflammatory responses. IL-1β is a major cause of severe inflammation in the mouse model of Crohn?s Disease, which makes IL-1β an important target for this disease.
NCBI Gene:
24494
Purity:
>97% by SDS-PAGE and analyzed by silver stain.
Target:
IL-1β
References
1. Dinarello, CA. et al. (1996) Blood 87: 2095
2. Yuan, J. et al. (1993) Cell 75: 641
3. Maeda, S. et al. (2005) Science 4: 735
Related Products
| Product Name | Product Code | Supplier | Anti-Human IL-1β | LEI-I-145 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Mouse IL-1β | LEI-I-162 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Rat IL-1β | LEI-I-169 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Human IL-1β | LEI-I-183 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Mouse IL-1β | LEI-I-205 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human IL-1β (Clone 8516) | LEI-I-629 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse IL-1β (Clone 30311) | LEI-I-659 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Rat IL-1β (Clone 38139) | LEI-I-672 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||